|Articles|March 1, 2018
- BioPharm International-03-01-2018
- Volume 31
- Issue 3
BioPharm International, March 2018 Issue (PDF)
Click the title above to open the BioPharm International March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
FDA Heightens Drive for Transparencyover 7 years ago
Current Challenges in Bioprocesses Developmentover 7 years ago
Characterizing a Bioprocess with Advanced Data Analyticsover 7 years ago
Computerized Systems Validationover 7 years ago
Regulatory Role in Bio/Pharma Progressover 7 years ago
Poseidon Takes on the Pharma Supply Chainover 7 years ago
Identifying and Controlling CPPs and CMAsover 7 years ago
Employing Spectroscopic Tools in Downstream Process Controlover 7 years ago
Biologic NMEs Maintain Strong Presence in 2017 Drug ApprovalsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Implications of the First Liquid IV Infliximab Biosimilar
2
GSK Bets $50M on LTZ’s Immune-Engager Platform for Next-Gen Cancer Treatment
3
Why 503B Compounding Pharmacies Choose Prefabricated POD® Cleanrooms
4
Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program
5
